Legato Capital Management LLC Invests $443,000 in CryoPort, Inc. $CYRX

Legato Capital Management LLC purchased a new stake in CryoPort, Inc. (NASDAQ:CYRX) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 46,188 shares of the company’s stock, valued at approximately $443,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Tower Research Capital LLC TRC raised its stake in CryoPort by 300.1% in the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock valued at $44,000 after purchasing an additional 4,375 shares in the last quarter. Whittier Trust Co. of Nevada Inc. acquired a new position in CryoPort in the third quarter valued at about $53,000. AlphaQuest LLC acquired a new position in CryoPort in the third quarter valued at about $79,000. Creative Planning acquired a new position in CryoPort in the second quarter valued at about $96,000. Finally, State of Wyoming raised its stake in CryoPort by 30.2% in the second quarter. State of Wyoming now owns 14,218 shares of the company’s stock valued at $106,000 after purchasing an additional 3,301 shares in the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

CryoPort Price Performance

Shares of CYRX stock opened at $14.02 on Thursday. The business’s 50 day simple moving average is $10.68 and its 200 day simple moving average is $9.77. CryoPort, Inc. has a one year low of $5.31 and a one year high of $14.36. The stock has a market capitalization of $706.61 million, a PE ratio of 10.39 and a beta of 1.75.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The business had revenue of $47.80 million for the quarter, compared to the consensus estimate of $44.86 million. CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%. As a group, research analysts expect that CryoPort, Inc. will post -0.74 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on CYRX. Wall Street Zen raised CryoPort from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Craig Hallum began coverage on CryoPort in a research report on Monday, March 30th. They issued a “buy” rating and a $15.00 target price on the stock. BTIG Research lifted their target price on CryoPort from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Weiss Ratings upgraded CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 6th. Finally, Needham & Company LLC lifted their target price on CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $14.69.

Insider Transactions at CryoPort

In related news, CFO Robert Stefanovich sold 38,700 shares of the stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $7.76, for a total value of $300,312.00. Following the completion of the sale, the chief financial officer directly owned 255,701 shares of the company’s stock, valued at approximately $1,984,239.76. This represents a 13.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Jerrell Shelton sold 7,918 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $63,344.00. Following the completion of the sale, the chief executive officer directly owned 1,054,501 shares of the company’s stock, valued at $8,436,008. The trade was a 0.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 59,939 shares of company stock valued at $471,183 over the last ninety days. 10.00% of the stock is owned by company insiders.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.